Strides Pharma Science Ltd is Rated Hold

Current Rating and Its Significance

MarketsMOJO’s 'Hold' rating for Strides Pharma Science Ltd indicates a balanced outlook for investors. It suggests that while the stock is not currently a strong buy, it also does not warrant a sell recommendation. Investors should consider maintaining their existing positions, monitoring the company’s developments closely, and weighing the stock’s valuation and financial trends before making new investment decisions.

Quality Assessment: Below Average Fundamentals

As of 23 June 2026, Strides Pharma Science Ltd exhibits below average quality metrics. The company’s long-term fundamental strength remains weak, with an average Return on Capital Employed (ROCE) of 8.83%. This figure reflects moderate efficiency in generating returns from its capital base. Over the past five years, net sales have grown at an annual rate of 7.94%, while operating profit has increased by 11.02% annually. These growth rates, though positive, are modest compared to industry leaders.

Additionally, the company’s ability to service debt is constrained, with a Debt to EBITDA ratio of 1.90 times, indicating a relatively high leverage level. This elevated debt burden could limit financial flexibility and increase risk during market downturns.

Valuation: Attractive Pricing Relative to Peers

Despite the quality concerns, Strides Pharma Science Ltd’s valuation remains attractive. The stock trades at an Enterprise Value to Capital Employed ratio of 2.5, which is below the average historical valuations of its pharmaceutical peers. This discount suggests that the market currently prices the stock conservatively, potentially offering value to investors willing to accept the associated risks.

Moreover, the company’s ROCE for the half-year period stands at a more encouraging 15.5%, signalling improved capital efficiency in recent months. This improvement supports the valuation appeal and underpins the 'Hold' rating.

Financial Trend: Very Positive Recent Performance

The latest data as of 23 June 2026 shows a very positive financial trend for Strides Pharma Science Ltd. The company reported a robust net profit growth of 54.96% in the most recent quarter ending March 2026. This marks the eleventh consecutive quarter of positive results, highlighting consistent operational performance.

Operating profit to interest coverage ratio reached a high of 5.77 times, indicating strong earnings relative to interest expenses. The half-year ROCE peaked at 17.96%, and the debt-equity ratio improved to a low of 0.57 times, reflecting a healthier balance sheet position. These factors collectively demonstrate the company’s improving financial health and operational resilience.

Technicals: Bullish Momentum Supports Stability

From a technical perspective, Strides Pharma Science Ltd is currently exhibiting bullish trends. The stock has delivered strong returns over various time frames as of 23 June 2026: a 1-day gain of 1.92%, a 1-week increase of 3.21%, and a 3-month surge of 25.37%. Year-to-date returns stand at 26.07%, while the one-year return is an impressive 37.19%.

These positive price movements suggest growing investor confidence and momentum, which may provide support for the stock in the near term. However, investors should remain cautious given the underlying fundamental challenges and market volatility.

Risks and Considerations

Investors should be mindful of certain risks associated with Strides Pharma Science Ltd. Notably, 27.27% of promoter shares are pledged, which can exert downward pressure on the stock price during market declines. High promoter pledging often signals potential liquidity concerns or financial stress, warranting close monitoring.

Furthermore, while the company’s recent profit growth is encouraging, its long-term growth rates and debt servicing capacity remain areas of concern. These factors contribute to the cautious 'Hold' stance, advising investors to weigh both the opportunities and risks carefully.

Summary for Investors

In summary, Strides Pharma Science Ltd’s 'Hold' rating reflects a nuanced view of the company’s current standing. While the stock benefits from attractive valuation and positive recent financial trends, its below average quality metrics and elevated debt levels temper enthusiasm. The bullish technical momentum offers some reassurance, but the significant promoter share pledging remains a cautionary factor.

Investors should consider maintaining existing holdings while monitoring quarterly results and debt metrics closely. New investors may wish to await further clarity on the company’s long-term growth prospects and balance sheet improvements before committing fresh capital.

Contextualising the Rating

The MarketsMOJO Mojo Score for Strides Pharma Science Ltd currently stands at 63.0, corresponding to the 'Hold' grade. This score represents a substantial improvement from the previous 'Sell' rating, which was assigned when the score was 40. The rating change occurred on 06 April 2026, reflecting the company’s evolving fundamentals and market performance. However, all financial data and returns discussed here are as of 23 June 2026, ensuring investors have the most recent and relevant information to guide their decisions.

Looking Ahead

Going forward, the company’s ability to sustain profit growth, manage debt prudently, and improve its fundamental quality will be key determinants of its rating trajectory. Investors should also watch for sector-wide developments in Pharmaceuticals & Biotechnology, which could influence Strides Pharma Science Ltd’s competitive positioning and valuation multiples.

Overall, the 'Hold' rating advises a cautious but attentive approach, recognising both the opportunities and challenges inherent in the stock’s current profile.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →